Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
J Immunother Cancer
; 7(1): 281, 2019 10 31.
Article
in En
| MEDLINE
| ID: mdl-31672171
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vulvitis
/
Uterine Cervical Neoplasms
/
Drug Resistance, Neoplasm
/
Antineoplastic Agents, Immunological
/
Nivolumab
Type of study:
Diagnostic_studies
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
J Immunother Cancer
Year:
2019
Document type:
Article
Affiliation country:
Country of publication: